Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

KT-621 is an investigational first-in-class once-daily, oral STAT6 degrader with dupilumab-like activity ... biologics with the convenience of oral administration, which, in turn, can transform ...